to prevent platelets from clumping together. Broken down into ab-ci-xi-mab, its name shows the drug to be a chimeric monoclonal antibody used on the cardiovascular system. This and the following two names would look the same if the 2009 convention were applied. The name of the breast cancer medication trastuzumab can be analyzed as tras-tu-zu-mab. Therefore, the drug is a humanized monoclonal antibody used against a tumor. Alacizumab pegol is a PEGylated humanized antibody targeting the circulatory system. Technetium (99mTc) pintumomab and technetium (99mTc) nofetumomab merpentan are radiolabeled antibodies, merpentan being a chelator that links the antibody nofetumomab to the radioisotope technetium-99m. Rozrolimupab is a polyclonal antibody. Broken down into rozro-lim-u-pab, its name shows the drug to be a human polyclonal antibody (-pab) acting on the immune system. Convention from 2009 to 2017 Olaratumab is an antineoplastic. Its name is composed of the components olara-t-u-mab. This shows that the drug is a human monoclonal antibody acting against tumors. The name of benralizumab, a drug designed for the treatment of asthma, has the components benra-li-zu-mab, marking it as a humanized antibody acting on the immune system. Convention from 2017 to 2021 Belantamab mafodotin (belan-ta-mab) is also an antineoplastic. It is conjugated to a cytotoxic agent that is chemically related to monomethyl auristatin E. See also List of monoclonal antibodies Monoclonal antibody therapy References nomen monoclonal